Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review
| العنوان: | Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review |
|---|---|
| المؤلفون: | Ran Zuo, Yajie Wang, Peng Chen, Cuicui Zhang, Li Lin |
| المصدر: | Thoracic Cancer Thoracic Cancer, Vol 11, Iss 9, Pp 2743-2748 (2020) |
| بيانات النشر: | John Wiley & Sons Australia, Ltd, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Pulmonary and Respiratory Medicine, Male, Lung Neoplasms, EGFR S768I, Afatinib, Case Report, Adenocarcinoma of Lung, Case Reports, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Osimertinib, Epidermal growth factor receptor, Lung cancer, Protein Kinase Inhibitors, EGFR inhibitors, Aged, rare mutation, biology, business.industry, EGFR G724S, General Medicine, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, epidermal growth factor receptor (EGFR), ErbB Receptors, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Icotinib, Mutation, Cancer research, biology.protein, Adenocarcinoma, Female, business, Tyrosine kinase, medicine.drug |
| الوصف: | Mutations in the epidermal growth factor receptor (EGFR) are drivers of a subset of lung cancers. In recent years, the treatment of non‐small cell lung cancer (NSCLC), especially with EGFR inhibitors, has made rapid progress, and the median progression‐free survival (PFS) of patients with EGFR gene‐sensitive mutations has been significantly prolonged. However, the response effect of some uncommon EGFR mutations to tyrosine kinase inhibitors (TKIs) remains unclear. Here, we present a patient with multiple EGFR mutations that highlights tumor heterogeneity leading to a mixed molecular response to targeted drugs and emphasizes the complexity of EGFR‐driven lung cancer. He received chemotherapy and molecular‐targeted treatment including icotinib, afatinib, osimertinib and afatinib + osimertinib. In conclusion, patients with lung adenocarcinoma harboring the EGFR S768I and G724S mutations appear less sensitive to icotinib than patients with sensitive EGFR. However, the patient in our report benefited from treatment with afatinib. Here, we hope to provide information for the treatment of rare and compound mutations in patients. Patients with lung adenocarcinoma harboring the EGFR S768I and G724S mutations appear less sensitive to first‐generation tyrosine kinase inhibitors than patients with sensitive EGFR.However, the patient benefited from treatment with afatinib. |
| اللغة: | English |
| تدمد: | 1759-7714 1759-7706 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99e4e5551796d49019216b64adb617ba http://europepmc.org/articles/PMC7471019 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....99e4e5551796d49019216b64adb617ba |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597714 17597706 |
|---|